<img src="https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7?size=2" nborder="0" align="left" hspace="5" vspace="5" title="22157.jpg" alt="Company Logo"/>Biologics, biosimilars and GLP-1 drugs are driving outsourced fill-finish, while scarce lyophilization capacity, RTU formats, bundled services and Asia-Pacific expansion create opportunities.Dublin, Aug. 20, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- The <a href="https://www.researchandmarkets.com/reports/6247560/sterile-injectables-cdmo-market-share?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=pvldd5&amp;utm_campaign=2330904+-+Global+Sterile+Injectables+CDMO+Industry+Forecast+Report+2026-2031+%7c+Rising+Demand+for+Outsourced+Sterile+Manufacturing+Drives+Market+Growth&amp;utm_exec=jocamsai" rel="nofollow" target="_blank" title="Sterile Injectables CDMO - Market Share Analysis, Industry Trends &amp; Statistics, Growth Forecasts (2026-2031)">"Sterile Injectables CDMO - Market Share Analysis, Industry Trends &amp; Statistics, Growth Forecasts (2026-2031)"</a> has been added to ResearchAndMarkets.com's offering. The global sterile injectables contract development and manufacturing organization (CDMO) market is projected to grow from USD 15.64 billion in 2025 and USD 17.13 billion in 2026 to USD 26.92 billion by 2031. The market is expected to register a compound annual growth rate (CAGR) of 9.47% from 2026 through 2031, supported by expanding biologics pipelines, limited in-house aseptic manufacturing capacity, and rising demand for specialized fill-finish services. Biologics Pipeline Expansion Strengthens Market Demand Biologics accounted for approximately 40% of the 55 novel drugs approved by the U.S. Food and Drug Administration in 2024, compared with 25% five years earlier. Advances in antibody engineering, gene therapies, biosimilars, antibody-drug conjugates, and bispecific antibodies are increasing demand for sterile injectables CDMOs capable of supporting clinical and commercial production. Patent expirations affecting major biologic therapies, including adalimumab and bevacizumab, have also expanded biosimilar development. However, relatively few mid-sized pharmaceutical and biotechnology companies operate validated biologics manufacturing suites. This capacity gap is benefiting CDMOs with expertise in cytotoxic handling, isolator technology, sterile fill-finish operations, and specialized containment. Limited In-House Aseptic Capacity Drives Outsourcing Building a dedicated aseptic manufacturing line can require more than USD 300 million and take up to five years. Combined with the financial risks associated with early-stage drug development, these costs encourage pharmaceutical and biotechnology companies to outsource sterile injectable manufacturing. Global fill-finish utilization exceeded 85% in 2024, while utilization rates for lyophilization lines were even higher. The resulting capacity constraints have created scheduling backlogs of 18 to 24 months. Virtual biotechnology companies, which represent more than 60% of early biologics developers, are especially dependent on CDMOs for services ranging from toxicology batches and formulation support to commercial manufacturing and product release. Lyophilization Capacity Remains a Key Market Constraint Global freeze-drying capacity is estimated to trail demand by 15% to 20%, with lead times for commercial-scale manufacturing campaigns extending to 18 to 24 months. New lyophilization lines typically cost USD 15 million to USD 25 million per unit and require 12 to 18 months for installation and validation. Energy costs associated with multi-day freeze-drying cycles have also increased by approximately 30% to 40% since 2022. These constraints can delay product launches or require sponsors to pursue liquid-stable formulations, which may involve additional regulatory filings and clinical bridging studies. CDMOs with established lyophilization capacity can command premium pricing, although higher fees may create challenges for cost-sensitive biosimilar developers. Additional sterile injectables CDMO market growth factors include increasing adoption of ready-to-use fill-finish formats and heightened regulatory scrutiny that encourages sponsors to work with experienced manufacturing partners. Fragmented regulatory requirements across emerging markets remain a challenge for companies pursuing international commercialization. Small Molecules Lead Revenue While Biologics Record Faster Growth Small molecules generated 62.34% of sterile injectables CDMO market revenue in 2025, supported by established hospital demand across anesthesia, oncology, and other therapeutic areas. Biologics are forecast to expand at a 10.34% CAGR through 2031, reflecting high product values, complex manufacturing requirements, and significant technical barriers to entry. Antibody-drug conjugates and GLP-1 analogs require specialized manufacturing capabilities that are available from fewer than 20 global providers. CDMOs operating both small-molecule and biologics lines can adjust capacity as development pipelines evolve, while biologics generally offer stronger margins due to higher batch values and longer periods of market exclusivity. Analytical and testing services represented 39.95% of segment revenue in 2025 as regulators increased expectations for potency, endotoxin, and extractables testing. Manufacturing services are projected to grow at a 9.67% CAGR as sponsors avoid the cost of building new cleanrooms. Modern fill-finish facilities are increasingly integrating robotic vial handling, automated inspection systems, and process analytical technologies to reduce operator contact, improve throughput, and accelerate batch disposition. Demand for bundled CDMO agreements is also rising. Pharmaceutical and biotechnology sponsors increasingly prefer a single partner for formulation development, analytical testing, sterile manufacturing, fill-finish, packaging, and commercial supply. This model reduces operational handoffs and supports faster, more consistent product development. Regional Sterile Injectables CDMO Market Outlook North America accounted for 45.25% of global market revenue in 2025, supported by major biotechnology clusters in Boston, North Carolina, and California. Investments in fill-finish capacity, including facilities serving GLP-1 products, reinforce the region's leadership. Although high labor costs present a challenge, strong regulatory credibility continues to make North American manufacturing capacity attractive for global drug launches. Europe maintains extensive aseptic manufacturing infrastructure across Germany, France, Italy, and Spain. Revised Annex 1 requirements have encouraged facility upgrades, while tax incentives are attracting new biologics investments. Spain continues to appeal to cost-conscious sponsors, and alignment with European good manufacturing practice standards supports regional quality consistency. Asia-Pacific is expected to be the fastest-growing regional market, registering a 10.48% CAGR through 2031. South Korea continues to expand its position as a global biologics manufacturing hub, while China is increasing capacity for domestic and export markets. India benefits from competitive operating costs and a large technical workforce, particularly for small-molecule projects. Continued regulatory improvements and successful multinational pharmaceutical audits are expected to strengthen Asia-Pacific's role in the global sterile injectables CDMO market. Key Topics Covered 1 Introduction 1.1 Study Assumptions &amp; Market Definition 1.2 Scope of the Study 2 Research Methodology 3 Executive Summary 4 Market Landscape 4.1 Market Overview 4.2 Market Drivers 4.2.1 Rapid Biologics Pipeline Expansion 4.2.2 Shortage of In-house Aseptic Capacity among Mid-size Pharma 4.2.3 Growing Demand for Ready-to-use (RTU) Fill-finish Formats 4.2.4 Heightened Regulatory Scrutiny Driving Outsourcing to Experts 4.2.5 Increase Prevalence of Chronic and Complex Diseases 4.2.6 Automation-enabled Micro-batch fill-finish for orphan drugs 4.3 Market Restraints 4.3.1 Limited Global Lyophilization Capacity Causing Schedule Bottlenecks 4.3.2 Highly Fragmented Regulatory Requirements Across Emerging Markets 4.3.3 Rising Glass-vial Shortages &amp; CCI failures 4.3.4 Talent Scarcity in High-potent Aseptic Suites 4.4 Value / Supply-Chain Analysis 4.5 Regulatory Landscape 4.6 Technological Outlook 4.7 Porter's Five Forces 4.7.1 Threat of New Entrants 4.7.2 Bargaining Power of Suppliers 4.7.3 Bargaining Power of Buyers 4.7.4 Threat of Substitutes 4.7.5 Industry Rivalry 5 Market Size &amp; Growth Forecasts (Value, USD) 5.1 By Molecule Type 5.1.1 Small Molecule 5.1.2 Large Molecule / Biologics 5.2 By Services 5.2.1 Formulation Development 5.2.2 Analytical and Testing Services 5.2.3 Manufacturing 5.2.4 Fill-Finish &amp; Packaging 5.2.5 Others 5.3 By Dosage Form 5.3.1 Vials and Ampoules 5.3.2 Prefilled Syringes 5.3.3 Speciality Injectables 5.3.4 Others 5.4 By End-User 5.4.1 Pharmaceutical Companies 5.4.2 Biotechnology Companies 5.4.3 Others 5.5 By Geography 5.5.1 North America 5.5.1.1 United States 5.5.1.2 Canada 5.5.1.3 Mexico 5.5.2 Europe 5.5.2.1 Germany 5.5.2.2 United Kingdom 5.5.2.3 France 5.5.2.4 Italy 5.5.2.5 Spain 5.5.2.6 Rest of Europe 5.5.3 Asia-pacific 5.5.3.1 China 5.5.3.2 Japan 5.5.3.3 India 5.5.3.4 South Korea 5.5.3.5 Australia 5.5.3.6 Rest of Asia-pacific 5.5.4 Middle East and Africa 5.5.4.1 GCC 5.5.4.2 South Africa 5.5.4.3 Rest of Middle East and Africa 5.5.5 South America 5.5.5.1 Brazil 5.5.5.2 Argentina 5.5.5.3 Rest of South America 6 Competitive Landscape 6.1 Market Concentration 6.2 Strategic Moves 6.3 Market Share Analysis 6.4 Company Profiles {(includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products &amp; Services, and Recent Developments)} 6.4.1 AbbVie Contract Manufacturing 6.4.2 Aenova Group 6.4.3 Ajinomoto Bio-Pharma 6.4.4 Alcami Corporation 6.4.5 Novo Holdings A/S (Catalent Inc.) 6.4.6 Delpharm 6.4.7 Fareva 6.4.8 Fresenius Kabi (mAbxience) 6.4.9 Jabil Inc (Pharmaceutics International Inc,) 6.4.10 Jubilant HollisterStier 6.4.11 Lonza Group AG 6.4.12 PCI Pharma Services 6.4.13 Recipharm (ETQ) 6.4.14 Samsung Biologics 6.4.15 Siegfried Holding AG 6.4.16 Thermo Fisher Scientific Inc. (Patheon) 6.4.17 Vetter Pharma 6.4.18 WuXi Biologics 7 Market Opportunities &amp; Future Outlook 7.1 White-Space &amp; Unmet-Need Assessment For more information about this report visit <a href="https://www.researchandmarkets.com/reports/6247560/sterile-injectables-cdmo-market-share?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=pvldd5&amp;utm_campaign=2330904+-+Global+Sterile+Injectables+CDMO+Industry+Forecast+Report+2026-2031+%7c+Rising+Demand+for+Outsourced+Sterile+Manufacturing+Drives+Market+Growth&amp;utm_exec=jocamsai" rel="nofollow" target="_blank" title="">https://www.researchandmarkets.com/r/pvjyog</a> About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. <pre>CONTACT: 
CONTACT: ResearchAndMarkets.com 
 Laura Wood,Senior Press Manager 
 press@researchandmarkets.com
 For E.S.T Office Hours Call 1-917-300-0470 
 For U.S./ CAN Toll Free Call 1-800-526-8630 
 For GMT Office Hours Call +353-1-416-8900 

</pre> <img alt="" src='https://ml.globenewswire.com/media/NmQ2YWNkNzAtMjdlNS00ZTRjLWEyMjAtZTg4OTgwMDAyY2EyLTEwMjY3MzctMjAyNi0wOC0yMC1lbg==/tiny/Research-and-Markets.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Global Sterile Injectables CDMO Industry Forecast Report 2026-2031 | Rising Demand for Outsourced Sterile Manufacturing Drives Market Growth

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn